**Supplemental digital content 3. Non-fatal serious adverse events reported from administration of dose 1 up to study end (Total vaccinated cohort)**

| Group | n | Serious adverse event description |
|---|---|---|
| <6S | 1 | Malaria and septicemia |
| | 1 | Malaria and gastroenteritis |
| <6NS | 4 | Gastroenteritis |
| | 2 | Malaria and gastroenteritis |
| | 1 | Malaria and pneumonia |
| | 1 | Urinary tract infection |
| 7-11S | 1 | Gastroenteritis |
| | 1 | Septicemia |
| 7-11NS | 2 | Gastroenteritis |
| | 1 | Malaria and bronchitis |
| | 1 | Enteritis |
| 12-23S | 1 | Osteomyelitis |
| | 1 | Malaria and pneumonia |
| 12-23NS | 1 | Malaria and septicemia |
| | 1 | Malaria and gastroenteritis |

Footnote: <6S, infants with SCD enrolled at 8–11 weeks of age, primed with 3 doses and boosted with PHiD-CV + DTPw-HBV/Hib + OPV vaccines at 2, 3, 4 and 9–10 months of age; <6NS, infants without SCD enrolled at 8–11 weeks of age, primed with 3 doses and boosted with PHiD-CV + DTPw-HBV/Hib + OPV vaccines at 2, 3, 4 and 9–10 months of age; 7-11S, children with SCD enrolled at 7–11 months of age, primed with 2 doses and boosted with PHiD-CV; 7-11NS, children without SCD enrolled at 7–11 months of age, primed with 2 doses and boosted with PHiD-CV ; 12-23S, children with SCD enrolled at 12–23 months of age, vaccinated with 2 doses of PHiD-CV; 12-23NS, children without SCD enrolled at 12–23 months of age, vaccinated with 2 doses of PHiD-CV; n, number of children reporting the serious adverse event.